Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from April 30, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 29, 2026 — +33.6% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$870.00 – $930.00Entry zone — fair-value band

$905.65Published — price the day we called it

$1,123.01Target — the price the thesis aimed for

$1,249.45Peak — highest point inside the window, not a realized return

$1,210.02Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 28 days.

At window close

+33.6%

realized, from the publication price to the last close inside the window

Peak gain

+38%

peak, from the publication price — not a realized return

S&P 500, same window

+1.8%

SPY over the identical days, dividend-adjusted

Window close

$1,210.02

last close inside the window, ended July 29, 2026

Peak price

$1,249.45

peak on July 7, 2026 — not a realized return

Days to target

The thesis — published April 30, 2026

Predicted growth

+24%

over the measurement window

Target price

$1,123.01

the price the thesis aimed for

Entry zone

$870.00 – $930.00

the fair-value band we waited for

Price at publication

$905.65

published April 30, 2026

Confidence

82%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly is the strongest big healthcare stock right now because recent quarterly results beat expectations, the company raised its outlook, and demand for key drugs Mounjaro and Zepbound is strong. The recent price dip looks healthy given investor selling, but valuation and competition in obesity drugs mean the investment case still has risk. Overall, the short-term reward looks appealing.

Primary drivers

Quarterly beat and higher outlook show revenue strength
Strong demand for Mounjaro and Zepbound drives growth
Recent pullback creates a more balanced buying setup
Obesity pipeline and category lead support premium valuation

How it played out

LLY: target reached in 28 days

Lyra published LLY at $905.65 with an expected 24% rise to $1,123.01. The thesis pointed to a quarterly beat, a higher outlook, strong demand for Mounjaro and Zepbound, a recent pullback, and the obesity pipeline. It also noted valuation and competition as risks.

LLY reached the target in 28 days. It later peaked at $1,249.45 on July 7, a 38% gain from publication, then ended the window at $1,210.02 on July 29. The peak and closing price were both above the target. The published thesis played out fully.

What happened during the window

On May 26, Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company. On June 7, Lilly reported results from analyses of Foundayo trials in women with obesity or overweight.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals